Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of CK-301 monotherapy in advanced cancers
2024-517536-22-00Phase 2Authorised
- Sponsor
- Checkpoint Therapeutics, Inc.
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of cosibelimab-ipdl in cutaneous squamous cell carcinoma (cSCC), sponsored by Checkpoint Therapeutics, Inc. Planned start Sep 2020; status: authorised.
02
Drugs
cosibelimab-ipdl
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-517536-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517536-22-00.